Navigation Links
Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
Date:9/26/2013

SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the commercial launch of Herceptin® SC in Europe has triggered a $10 million milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche. This time-saving subcutaneous formulation of Herceptin (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) received marketing authorization from the European Commission on August 28, 2013 for the treatment of patients with HER2-positive breast cancer and was launched upon approval. Herceptin SC reduces treatment times and enhances convenience compared to the standard intravenous (IV) form.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"With pricing on par with the intravenous formulation, Herceptin SC represents a compelling treatment alternative for breast cancer patients in Europe, and we congratulate Roche on making this time-saving therapy available to patients in Europe so quickly," said Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme.  "This will be the third commercial product using our rHuPH20 enzyme and represents a significant achievement for our technology and company as a whole."

About Breast Cancer
Breast cancer is the most common cancer among women worldwide.1 Each year, about 1.4 million new cases of breast cancer are diagnosed worldwide, and over 450,000 women will die of the disease annually.1 In HER2-positive breast cancer, increased quantities of the human epidermal growth factor receptor 2 (HER2) are present on the surface of the tumor cells. Thi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
2. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
3. Acella Pharmaceuticals Announces a New Addition to the Commercial Team
4. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
5. New Executive Vice President Commercial Appointed
6. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
7. Pharmaceutical Commercial Leaders Seek Global Benchmarks for More Informed Decision-Making
8. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
9. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
10. Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell Technologies
11. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
(Date:10/20/2014)... Lpath, Inc. (NASDAQ: LPTN ... official notification from the European Patent Office that ... supporting its iSONEP™ and ASONEP™ programs. ... 2087002, claims compositions of matter related to sonepcizumab, ... iSONEP and ASONEP. Sonepcizumab is an antibody that ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... cherry tree saplings were planted in Central Park of ... County Park System, located in Parsippany Troy-Hills.  The planting ... 100th anniversary of the historic gift of Japanese flowering ...  More than 75 Daiichi Sankyo employee volunteers partnered with ...
... 21, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) announced ... with sales revenues during the three months ended September ... for the third quarter is a result of instrument ... Centers and Surgery Centers across the United States. ...
Cached Medicine Technology:Daiichi Sankyo, Inc. Brings the Legacy of Washington, DC Cherry Trees to New Jersey 2Daiichi Sankyo, Inc. Brings the Legacy of Washington, DC Cherry Trees to New Jersey 3Daiichi Sankyo, Inc. Brings the Legacy of Washington, DC Cherry Trees to New Jersey 4Solos Endoscopy Finishes the 3rd Quarter Strong 2
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3
... home-based treatment for hand eczema is just as effective ... to // a new study. Eczema is an inflammatory ... scaling. ,Researchers examined 158 patients with moderate to ... About half the patients followed a home-based program taking ...
... therapy of acupuncture can help those suffering from arthritis ... ,A current multi-location trial included 570 patients ages ... were placed in three groups. One hundred and ninety ... followed a self-help course to manager their condition. The ...
... worldwide. A model based on the findings of a clinical ... severity of acute appendicitis, // according to a new study. ... 89 who underwent an appendectomy within three days of an ... the actual severity of acute appendicitis. The study showed CT, ...
... million people worldwide and is caused by abnormal surges in ... seizures. More than half of those with epilepsy can live ... is under way to determine just how effective surgery is ... epilepsy, the most common form of the disorder. Typically, about ...
... suggests getting active can help elderly patients who have trouble ... between the ages of 67 and 86 in a 90-minute ... exercise followed by 30 minutes of seated social activity and ... in the morning or in the evening, with all participants ...
... pain relief and improves function for people with ... effective complement to Normal care. This study was ... Alternative Medicine (NCCAM) and the National Institute of ... components of the National Institutes of Health.// The ...
Cached Medicine News:Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 2Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 3
Rheumatoid factor screening...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgica...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
Medicine Products: